Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
Abstract This prospective, nonrandomized, open-label phase 2 trial (Chinese Clinical Trial Registry, ChiCTR2200061906) aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in patients with locally advanced gastroesophageal junction adenocarcinoma...
Saved in:
Main Authors: | Run-Cong Nie, Shu-Qiang Yuan, Ya Ding, Yong-Ming Chen, Yuan-Fang Li, Cheng-Cai Liang, Mu-Yan Cai, Guo-Ming Chen, Wei Wang, Xiao-Wei Sun, De-Sheng Weng, Dan-Dan Li, Jing-Jing Zhao, Xiao-Jiang Chen, Yuan-Xiang Guan, Zhi-Min Liu, Yao Liang, Ma Luo, Jun Chi, Hai-Bo Qiu, Zhi-Wei Zhou, Xiao-Shi Zhang, Ying-Bo Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2025-02-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-025-02160-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: Multi-organ injuries induced by tislelizumab
by: Man Yuan, et al.
Published: (2025-02-01) -
Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis
by: Zakari Shaibu, et al.
Published: (2024-10-01) -
Gastroesophageal junction adenocarcinoma. A case report
by: Marcos Félix Osorio Pagola, et al.
Published: (2010-12-01) -
Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01) -
Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
by: Yuan Tian, et al.
Published: (2021-01-01)